HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Research | Clinical Cancer Research |
Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 7, Issue 2 147-160, Copyright © 1996 by American Association of Cancer Research
ARTICLES |
A Gualandris, M Rusnati, M Belleri, EE Nelli, M Bastaki, MP Molinari-Tosatti, F Bonardi, S Parolini, A Albini, L Morbidelli, M Ziche, A Corallini, L Possati, A Vacca, D Ribatti and M Presta
Department of Biomedical Sciences and Biotechnology, University of Brescia, Italy.
Basic fibroblast growth factor (bFGF) is expressed in vascular endothelium during tumor neovascularization and angioproliferative diseases. The ultimate significance of this observation is poorly understood. We have investigated the biological consequences of endothelial cell activation by endogenous bFGF in a mouse aortic endothelial cell line stably transfected with a retroviral expression vector harboring a human bFGF cDNA. Selected clones expressing M(r) 24,000, M(r) 22,000, and/or M(r) 18,000 bFGF isoforms were characterized by a transformed morphology and an increased saturation density. bFGF transfectants showed invasive behavior and sprouting activity in three-dimensional fibrin gels and formed a complex network of branching cord-like structures connecting foci of infiltrating cells when seeded on laminin-rich basement membrane matrix (Matrigel). The invasive and morphogenetic behavior was prevented by anti-bFGF antibody, revealing the autocrine modality of the process. The biological consequences of this autocrine activation were investigated in vivo. bFGF-transfected cells gave rise to highly vascularized lesions resembling Kaposi's sarcoma when injected in nude mice and induced angiogenesis in avascular rabbit cornea. When injected into the allantoic sac of the chick embryo, they caused an increase in vascular density and formation of hemangiomas in the chorioallantoic membrane. In conclusion, bFGF-overexpressing endothelial cells acquired an angiogenic phenotype and recruit quiescent endothelium originating angioproliferative lesions in vivo. These findings demonstrate that bFGF overexpression exerts an autocrine role for endothelial cells and support the notion that tumor neovascularization and angioproliferative diseases can be triggered by stimuli that induce vascular endothelium to produce its own autocrine factor(s).
This article has been cited by other articles:
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. Diane, N. Nikolic, A. P. Rudecki, S. M. King, D. J. Bowie, and S. L. Gray PACAP is essential for the adaptive thermogenic response of brown adipose tissue to cold exposure J. Endocrinol., September 1, 2014; 222(3): 327 - 339. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() E. Rousselet, S. Traver, Y. Monnet, A. Perrin, N. Mandjee, A. Hild, E. C. Hirsch, T. S. Zheng, and S. Hunot Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Induces Astrocyte Proliferation through the Activation of Transforming-Growth Factor-{alpha}/Epidermal Growth Factor Receptor Signaling Pathway Mol. Pharmacol., November 1, 2012; 82(5): 948 - 957. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. Liekens, A. Bronckaers, M. Belleri, A. Bugatti, R. Sienaert, D. Ribatti, B. Nico, A. Gigante, E. Casanova, G. Opdenakker, et al. The Thymidine Phosphorylase Inhibitor 5'-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist Mol. Cancer Ther., April 1, 2012; 11(4): 817 - 829. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() F. Finetti, S. Donnini, A. Giachetti, L. Morbidelli, and M. Ziche Prostaglandin E2 Primes the Angiogenic Switch via a Synergic Interaction With the Fibroblast Growth Factor-2 Pathway , September 25, 2009; 105(7): 657 - 666. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Belleri, D. Ribatti, M. Savio, L. A. Stivala, L. Forti, E. Tanghetti, P. Alessi, D. Coltrini, A. Bugatti, S. Mitola, et al. {alpha}v{beta}3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers Mol. Cancer Ther., December 1, 2008; 7(12): 3761 - 3770. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. Leali, E. Moroni, F. Bussolino, and M. Presta Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement J. Biol. Chem., July 6, 2007; 282(27): 19676 - 19684. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. Liekens, S. Gijsbers, E. Vanstreels, D. Daelemans, E. De Clercq, and S. Hatse The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells Mol. Pharmacol., March 1, 2007; 71(3): 695 - 703. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() H. Stabile, S. Mitola, E. Moroni, M. Belleri, S. Nicoli, D. Coltrini, F. Peri, A. Pessi, L. Orsatti, F. Talamo, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor Blood, March 1, 2007; 109(5): 1834 - 1840. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al. Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4'-Trimethoxystilbene Mol. Pharmacol., May 1, 2005; 67(5): 1451 - 1459. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Presta, P. Oreste, G. Zoppetti, M. Belleri, E. Tanghetti, D. Leali, C. Urbinati, A. Bugatti, R. Ronca, S. Nicoli, et al. Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists , January 1, 2005; 25(1): 71 - 76. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Rusnati, M. Camozzi, E. Moroni, B. Bottazzi, G. Peri, S. Indraccolo, A. Amadori, A. Mantovani, and M. Presta Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis Blood, July 1, 2004; 104(1): 92 - 99. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() L. Morbidelli, S. Donnini, F. Chillemi, A. Giachetti, and M. Ziche Angiosuppressive and Angiostimulatory Effects Exerted by Synthetic Partial Sequences of Endostatin Clin. Cancer Res., November 1, 2003; 9(14): 5358 - 5369. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. Leali, P. Dell'Era, H. Stabile, B. Sennino, A. F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, and M. Presta Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis J. Immunol., July 15, 2003; 171(2): 1085 - 1093. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. Leali, M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives J. Biol. Chem., October 12, 2001; 276(41): 37900 - 37908. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. Liekens, J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir Cancer Res., July 1, 2001; 61(13): 5057 - 5064. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. V. Bhagwat, J. Lahdenranta, R. Giordano, W. Arap, R. Pasqualini, and L. H. Shapiro CD13/APN is activated by angiogenic signals and is essential for capillary tube formation Blood, February 1, 2001; 97(3): 652 - 659. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors Cancer Res., January 1, 2001; 61(1): 309 - 317. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. W. Baish and R. K. Jain Fractals and Cancer Cancer Res., July 1, 2000; 60(14): 3683 - 3688. [Abstract] [Full Text] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. Y. Pan, W. E. Fieles, A. M. White, M. M. Egerton, and D. S. Silberstein Ges, a Human Gtpase of the Rad/Gem/Kir Family, Promotes Endothelial Cell Sprouting and Cytoskeleton Reorganization J. Cell Biol., May 29, 2000; 149(5): 1107 - 1116. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() R. Mohan, J. Sivak, P. Ashton, L. A. Russo, B. Q. Pham, N. Kasahara, M. B. Raizman, and M. E. Fini Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B J. Biol. Chem., April 7, 2000; 275(14): 10405 - 10412. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() R. Giuliani, M. Bastaki, D. Coltrini, and M. Presta Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2 J. Cell Sci., August 1, 1999; 112(15): 2597 - 2606. [Abstract] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. Liekens, E. Verbeken, M. Vandeputte, E. De Clercq, and J. Neyts A Novel Animal Model for Hemangiomas: Inhibition of Hemangioma Development by the Angiogenesis Inhibitor TNP-470 Cancer Res., May 1, 1999; 59(10): 2376 - 2383. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Presta, M. Rusnati, M. Belleri, L. Morbidelli, M. Ziche, and D. Ribatti Purine Analogue 6-Methylmercaptopurine Riboside Inhibits Early and Late Phases of the Angiogenesis Process Cancer Res., May 1, 1999; 59(10): 2417 - 2424. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. Vacca, D. Ribatti, M. Presta, M. Minischetti, M. Iurlaro, R. Ria, A. Albini, F. Bussolino, and F. Dammacco Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma Blood, May 1, 1999; 93(9): 3064 - 3073. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Ziche, A. Parenti, F. Ledda, P. Dell'Era, H. J. Granger, C. A. Maggi, and M. Presta Nitric Oxide Promotes Proliferation and Plasminogen Activator Production by Coronary Venular Endothelium Through Endogenous bFGF , June 19, 1997; 80(6): 845 - 852. [Abstract] [Full Text] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Bastaki, E. E. Nelli, P. Dell'Era, M. Rusnati, M. P. Molinari-Tosatti, S. Parolini, R. Auerbach, L. P. Ruco, L. Possati, and M. Presta Basic Fibroblast Growth Factor Induced Angiogenic Phenotype in Mouse Endothelium : A Study of Aortic and Microvascular Endothelial Cell Lines , March 1, 1997; 17(3): 454 - 464. [Abstract] [Full Text] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. Leali, M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives J. Biol. Chem., July 24, 2001; (2001) 105163200. [Abstract] [PDF] ![]() |
![]() |
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Research | Clinical Cancer Research |
Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
Molecular Cancer Research | Cell Growth & Differentiation |